SI2582683T1 - Treatment of gout and hyperuricemia - Google Patents
Treatment of gout and hyperuricemia Download PDFInfo
- Publication number
- SI2582683T1 SI2582683T1 SI201131474T SI201131474T SI2582683T1 SI 2582683 T1 SI2582683 T1 SI 2582683T1 SI 201131474 T SI201131474 T SI 201131474T SI 201131474 T SI201131474 T SI 201131474T SI 2582683 T1 SI2582683 T1 SI 2582683T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- use according
- allopurinol
- alopurinol
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract 4
- 201000005569 Gout Diseases 0.000 title claims 3
- 201000001431 Hyperuricemia Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- FVYMVLTWIBGEMC-UHFFFAOYSA-M sodium;2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetate Chemical compound [Na+].[O-]C(=O)CSC1=NN=C(Br)N1C(C1=CC=CC=C11)=CC=C1C1CC1 FVYMVLTWIBGEMC-UHFFFAOYSA-M 0.000 claims abstract 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 14
- 229960003459 allopurinol Drugs 0.000 claims 9
- FGQFOYHRJSUHMR-UHFFFAOYSA-N lesinurad Chemical compound OC(=O)CSC1=NN=C(Br)N1C(C1=CC=CC=C11)=CC=C1C1CC1 FGQFOYHRJSUHMR-UHFFFAOYSA-N 0.000 claims 5
- 229960003838 lesinurad Drugs 0.000 claims 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 229940116269 uric acid Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35500410P | 2010-06-15 | 2010-06-15 | |
| US41144910P | 2010-11-08 | 2010-11-08 | |
| US201161430522P | 2011-01-06 | 2011-01-06 | |
| US201161489420P | 2011-05-24 | 2011-05-24 | |
| PCT/US2011/040398 WO2011159732A1 (en) | 2010-06-15 | 2011-06-14 | Treatment of gout and hyperuricemia |
| EP11796324.9A EP2582683B1 (en) | 2010-06-15 | 2011-06-14 | Treatment of gout and hyperuricemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2582683T1 true SI2582683T1 (en) | 2018-07-31 |
Family
ID=45348529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201131474T SI2582683T1 (en) | 2010-06-15 | 2011-06-14 | Treatment of gout and hyperuricemia |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9216179B2 (enExample) |
| EP (1) | EP2582683B1 (enExample) |
| JP (1) | JP5964821B2 (enExample) |
| CA (1) | CA2802407C (enExample) |
| CY (1) | CY1120473T1 (enExample) |
| DK (1) | DK2582683T3 (enExample) |
| ES (1) | ES2670700T3 (enExample) |
| HR (1) | HRP20180780T1 (enExample) |
| HU (1) | HUE038265T2 (enExample) |
| LT (1) | LT2582683T (enExample) |
| NO (1) | NO2019008I1 (enExample) |
| PL (1) | PL2582683T3 (enExample) |
| PT (1) | PT2582683T (enExample) |
| RS (1) | RS57275B1 (enExample) |
| SI (1) | SI2582683T1 (enExample) |
| SM (1) | SMT201800266T1 (enExample) |
| TR (1) | TR201806828T4 (enExample) |
| WO (1) | WO2011159732A1 (enExample) |
| ZA (1) | ZA201300055B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2560642A4 (en) | 2010-03-30 | 2013-12-18 | Ardea Biosciences Inc | TREATMENT OF GICHT |
| EP2582683B1 (en) * | 2010-06-15 | 2018-03-21 | Ardea Biosciences, Inc. | Treatment of gout and hyperuricemia |
| EP3501520A1 (en) | 2011-11-03 | 2019-06-26 | Ardea Biosciences, Inc. | 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same |
| AR091651A1 (es) | 2012-07-03 | 2015-02-18 | Ardea Biosciences Inc | Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico |
| US8883857B2 (en) | 2012-12-07 | 2014-11-11 | Baylor College Of Medicine | Small molecule xanthine oxidase inhibitors and methods of use |
| CN103613552A (zh) * | 2013-12-02 | 2014-03-05 | 苏州晶云药物科技有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法 |
| CN103755651A (zh) * | 2013-12-23 | 2014-04-30 | 苏州晶云药物科技有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法 |
| US9969701B2 (en) | 2013-12-20 | 2018-05-15 | Crystal Pharmatech Co., Ltd. | Salts and co-crystals of lesinurad |
| JP2015160847A (ja) * | 2014-02-28 | 2015-09-07 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 小分子のキサンチンオキシダーゼ阻害剤および使用方法 |
| CN105622531A (zh) | 2015-04-03 | 2016-06-01 | 南京明德新药研发股份有限公司 | 轴手性异构体及其制备方法和制药用途 |
| WO2016203436A1 (en) * | 2015-06-19 | 2016-12-22 | Dr. Reddy's Laboratories Limited | Amorphous and amorphous solid dispersion of lesinurad and their preparation |
| EP3112334A1 (en) | 2015-06-29 | 2017-01-04 | DPx Fine Chemicals Austria GmbH & CoKG | Process for manufacturing 1-cyclopropyl-naphthalenes |
| PE20181521A1 (es) * | 2015-12-08 | 2018-09-24 | Ardea Biosciences Inc | Composicion farmaceutica que comprende un potente inhibidor de urat1 |
| US11700979B2 (en) | 2018-10-26 | 2023-07-18 | The Procter & Gamble Company | Sanitary tissue product rolls |
| CA3060211C (en) | 2018-10-26 | 2025-05-13 | The Procter & Gamble Company | TOILET PAPER ROLLS |
| CA3060193C (en) | 2018-10-26 | 2023-05-09 | The Procter & Gamble Company | Paper towel rolls |
| US11633076B2 (en) | 2018-10-26 | 2023-04-25 | The Procter & Gamble Company | Sanitary tissue product rolls |
| US20220288038A1 (en) * | 2019-08-21 | 2022-09-15 | The University Of Tokyo | Abcc11 inhibitor |
| CN110824067B (zh) * | 2019-12-11 | 2024-12-27 | 天津药物研究院有限公司 | 一种非布司他中基因毒性杂质的检测方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005063788A1 (ja) | 2003-12-26 | 2005-07-14 | Kissei Pharmaceutical Co., Ltd. | ベンズイミダゾール誘導体及びその医薬用途 |
| US20060189811A1 (en) | 2004-07-23 | 2006-08-24 | Fujiyakuhin Co., Ltd. | Process for producing 1,2,4-triazole compound and intermediate therefor |
| WO2007050087A1 (en) | 2004-08-25 | 2007-05-03 | Ardea Biosciences, Inc. | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS |
| DK2135608T3 (da) | 2004-08-25 | 2012-01-23 | Ardea Biosciences Inc | S-triazolyl-alfa-mercaptoacetanilider som inhibitorer for HIV-revers transkriptase |
| CN101646440A (zh) | 2007-01-19 | 2010-02-10 | 武田制药北美公司 | 使用黄嘌呤氧化还原酶抑制剂和抗炎剂预防痛风突发或减少痛风突发次数的方法 |
| ME01294B (me) | 2007-11-27 | 2013-06-20 | Ardea Biosciences Inc | Nova jedinjenja i kompozicije i metode upotrebe |
| US8242154B2 (en) * | 2008-09-04 | 2012-08-14 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
| US8173690B2 (en) * | 2008-09-04 | 2012-05-08 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
| CA2736117C (en) | 2008-09-04 | 2013-11-19 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
| US20100160351A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| EP2432774A4 (en) * | 2009-05-20 | 2013-01-02 | Ardea Biosciences Inc | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID RATES |
| EP2266966A1 (en) | 2009-06-11 | 2010-12-29 | Chemo Ibérica, S.A. | A process for the preparation of febuxostat |
| MX2012007925A (es) | 2010-01-08 | 2012-08-03 | Ardea Biosciences Inc | Formas polimorficas, cristalinas y de mesofase de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-ilti o)acetato de sodio, y usos de las mismas. |
| EP2560642A4 (en) | 2010-03-30 | 2013-12-18 | Ardea Biosciences Inc | TREATMENT OF GICHT |
| EP2582683B1 (en) * | 2010-06-15 | 2018-03-21 | Ardea Biosciences, Inc. | Treatment of gout and hyperuricemia |
| ES2706066T3 (es) * | 2010-07-02 | 2019-03-27 | Univ Health Network | Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas |
| US20130296345A1 (en) * | 2010-10-15 | 2013-11-07 | Ardea Biosciences, Inc. | Methods for treating hyperuricemia and related diseases |
| LT2658846T (lt) | 2010-12-30 | 2017-02-27 | Ardea Biosciences, Inc. | 2-(5-brom-4-(4-ciklopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acto rūgšties polimorfinės formos ir jų panaudojimas |
| ES2633762T3 (es) | 2011-05-24 | 2017-09-25 | Ardea Biosciences, Inc. | Hipertensión e hiperuricemia |
-
2011
- 2011-06-14 EP EP11796324.9A patent/EP2582683B1/en not_active Revoked
- 2011-06-14 SM SM20180266T patent/SMT201800266T1/it unknown
- 2011-06-14 PT PT117963249T patent/PT2582683T/pt unknown
- 2011-06-14 ES ES11796324.9T patent/ES2670700T3/es active Active
- 2011-06-14 TR TR2018/06828T patent/TR201806828T4/tr unknown
- 2011-06-14 US US13/704,192 patent/US9216179B2/en active Active
- 2011-06-14 RS RS20180571A patent/RS57275B1/sr unknown
- 2011-06-14 WO PCT/US2011/040398 patent/WO2011159732A1/en not_active Ceased
- 2011-06-14 SI SI201131474T patent/SI2582683T1/en unknown
- 2011-06-14 DK DK11796324.9T patent/DK2582683T3/en active
- 2011-06-14 JP JP2013515459A patent/JP5964821B2/ja not_active Expired - Fee Related
- 2011-06-14 HU HUE11796324A patent/HUE038265T2/hu unknown
- 2011-06-14 CA CA2802407A patent/CA2802407C/en not_active Expired - Fee Related
- 2011-06-14 LT LTEP11796324.9T patent/LT2582683T/lt unknown
- 2011-06-14 HR HRP20180780TT patent/HRP20180780T1/hr unknown
- 2011-06-14 PL PL11796324T patent/PL2582683T3/pl unknown
-
2013
- 2013-01-03 ZA ZA2013/00055A patent/ZA201300055B/en unknown
-
2015
- 2015-11-12 US US14/939,963 patent/US20160143889A1/en not_active Abandoned
-
2018
- 2018-05-18 CY CY20181100520T patent/CY1120473T1/el unknown
- 2018-09-19 US US16/135,153 patent/US20190015392A1/en not_active Abandoned
-
2019
- 2019-02-19 NO NO2019008C patent/NO2019008I1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9216179B2 (en) | 2015-12-22 |
| US20160143889A1 (en) | 2016-05-26 |
| US20190015392A1 (en) | 2019-01-17 |
| DK2582683T3 (en) | 2018-06-06 |
| HUE038265T2 (hu) | 2018-10-29 |
| RS57275B1 (sr) | 2018-08-31 |
| SMT201800266T1 (it) | 2018-07-17 |
| EP2582683B1 (en) | 2018-03-21 |
| ZA201300055B (en) | 2018-05-30 |
| CA2802407A1 (en) | 2011-12-22 |
| PL2582683T3 (pl) | 2018-08-31 |
| ES2670700T3 (es) | 2018-05-31 |
| WO2011159732A1 (en) | 2011-12-22 |
| LT2582683T (lt) | 2018-06-11 |
| US20130178484A1 (en) | 2013-07-11 |
| NO2019008I1 (no) | 2019-02-19 |
| JP2013528650A (ja) | 2013-07-11 |
| PT2582683T (pt) | 2018-05-25 |
| CA2802407C (en) | 2018-01-23 |
| EP2582683A1 (en) | 2013-04-24 |
| EP2582683A4 (en) | 2014-04-30 |
| HRP20180780T1 (hr) | 2018-07-13 |
| CY1120473T1 (el) | 2019-07-10 |
| TR201806828T4 (tr) | 2018-06-21 |
| JP5964821B2 (ja) | 2016-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2582683T1 (en) | Treatment of gout and hyperuricemia | |
| SI2529622T1 (en) | Inhibitors of bruton's tyrosine kinase | |
| TN2011000446A1 (en) | 3h-imidazo [4,5-c]pyridine-6-carboxamides as anti-inflammatory agents | |
| BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
| MX2012007410A (es) | Compuestos antivirales novedosos. | |
| CL2012001841A1 (es) | Polimorfo cristalino de la forma a de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetato de sodio; método de preparación; composición farmacéutica; y su uso para el tratamiento o prevención de hiperuricemia o una enfermedad causada por niveles elevados de ácido úrico. | |
| NZ610315A (en) | Antiviral condensed heterocyclic compounds | |
| BR112013017779A2 (pt) | derivados de oxazina e seu uso no tratamento de distúrbios neurológicos | |
| WO2008054454A3 (en) | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | |
| WO2010088000A3 (en) | Antifibrotic compounds and uses thereof | |
| BR112013032974A2 (pt) | "derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas". | |
| MX2011012122A (es) | Derivados de tiofeno. | |
| UA104021C2 (ru) | ПРОИЗВОДНЫЕ ТИЕНО[2,3-b]ПИРИДИНА КАК ИНГИБИТОРЫ РЕПЛИКАЦИИ ВИРУСА | |
| HRP20151000T1 (hr) | Antivirusni spojevi | |
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| CO6241104A2 (es) | "composiciones farmaceuticas que comprende {4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil}-5-cloro-tiofen-2-il-sulfonilurea o sales de la misma para la inhibicion de la agregacion de plaquetas inducidas por adp" | |
| EP2796450A4 (en) | 6-AMINOPYRIDIN-3-OL DERIVATIVES OR PHARMACEUTICAL SALTS AND / OR PHARMACEUTICAL COMPOSITION THEREOF AS ACTIVE AGENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | |
| UA110012C2 (uk) | Лікарські форми для перорального застосування, що містять ацетат лікарбазепіну | |
| PE20081578A1 (es) | Formulacion en polvo de valganciclovir | |
| BR112014028813A2 (pt) | 5-amino[1,4]tiazinas como inibidores bace1 | |
| HRP20211046T1 (hr) | Upotreba derivata benzimidazola kod noćnog proboja kiseline | |
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| HRP20120867T1 (hr) | Selurampanel | |
| MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| JP2008088189A5 (enExample) |